市場調查報告書

獸醫腫瘤學的全球市場: 市場規模,佔有率,趨勢分析 - 各治療方法、動物的種類、癌症的種類、地區

Veterinary Oncology Market Size, Share & Trends Analysis Report By Therapy, By Animal Type, By Cancer Type, By Region, And Segment Forecasts, 2020 - 2027

出版商 Grand View Research, Inc. 商品編碼 932835
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
獸醫腫瘤學的全球市場: 市場規模,佔有率,趨勢分析 - 各治療方法、動物的種類、癌症的種類、地區 Veterinary Oncology Market Size, Share & Trends Analysis Report By Therapy, By Animal Type, By Cancer Type, By Region, And Segment Forecasts, 2020 - 2027
出版日期: 2020年04月01日內容資訊: 英文 120 Pages
簡介

獸醫腫瘤學的全球市場規模在2020年∼2027年間,預測將以10.7%的年複合成長率發展,市場規模到2027年將達到4億4,700萬美元。寵物的癌症盛行率的增加和獸醫診斷的需求預期在預測期間促進市場成長。

本報告提供全球獸醫腫瘤學市場調查,市場概要,各技術、用途、治療方面,動物,各癌症種類、地區的市場規模的變化與預測,市場佔有率,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查手法和範圍

  • 市場區隔和範圍
  • 調查手法
  • 資訊採購
  • 資訊分析
  • 市場形成與驗證
  • 模式詳細內容
  • 二級資訊來源的清單
  • 一級資訊來源的清單
  • 簡稱
  • 目的

第2章 摘要整理

  • 市場預測
  • 各市場區隔預測
  • 競爭考察

第3章 市場變數、趨勢、範圍

  • 市場系統預測
  • 滲透與成長預測製圖(各技術,2019 )
  • 用戶的觀點分析
  • 主要的終端用戶的清單
  • 法律規範
  • 科技概要
  • 市場動態
  • 產業分析-搬運工人
  • SWOT分析,各要因(政治、法律,經濟,社會,技術)
  • 主要交易與策略性聯盟

第4章 競爭分析

  • 市場參加分類
  • 競爭分析

第5章 獸醫腫瘤學全球市場:治療類型分析

  • 治療類型商務分析

第6章 獸醫腫瘤學全球市場:動物類型

  • 動物類型分析

第7章 獸醫腫瘤學全球市場:癌症類型

  • 癌症的種類商務分析

第8章 獸醫腫瘤學全球市場:各地區分析(治療方法,動物的種類,癌症的種類 2016年∼2027年)

  • 佔有率分析,2019及2027
  • 儀表板
  • 概述
  • 市場規模,及預測與趨勢分析,從2019年到2027年

第9章 企業簡介

  • Boehringer Ingelheim International GmbH
  • Elanco
  • Zoetis
  • PetCure Oncology
  • Accuray Incorporated
  • Varian Medical System, Inc.
  • Nippon Zenyaku Kogyo Co., Ltd.
  • Morphogenesis, Inc.
  • Karyopharm Therapeutics, Inc.,
  • Regeneus Ltd.
  • One Health
目錄
Product Code: GVR-4-68038-182-5

The global veterinary oncology market size is expected to reach USD 447.0 million by 2027, expanding at a CAGR of 10.7% over the forecast period, according to a new report by Grand View Research, Inc. Increasing prevalence of cancer in pets and demand for veterinary diagnostics are projected to drive the market over the forecast period.

Adoption of canine cancer registry globally to estimate cancer incidences is another driving factor for the market growth. According to frontiers in Veterinary Science in February 2019, the Swiss Canine Cancer Registry (SCCR) was used as a data source and was compiled for future comparative studies of canine and human cancers. This database is further helpful in mitigating the incidence of malignant tumors in the human population, thereby driving the market growth.

Researchers carrying out studies focused on veterinary oncology are further boosting the veterinary oncology market growth. For instance, University of Illinois in August 2017, carried out study that involves more precise detection of metastasis (spread of cancer through the body) for head and neck tumors in dogs. Moreover, the market players are also focusing on new product innovation and strategic collaborations. For instance, in 2018 AdvaVet, a subsidiary of Oasmia Pharmaceutical AB, developed XR17 technology, which is nanoparticle formulation based that makes a single Active Pharmaceutical Ingredient (API) or multiple APIs water soluble. It is a combination therapy and is also a standard treatment for a number of cancer diseases in pet animals.

Further key findings from the report suggest:

Increasing prevalence of cancer in animals, clinical trial studies to evaluate safety and effectiveness of cancer therapeutics, and technological advancements in veterinary oncology treatment are anticipated to create growth opportunities in the market

The chemotherapy segment is anticipated to account for the largest revenue share over the coming years owing to its increasing adoption either alone or in combination with other therapies

The canine segment held the largest revenue in 2019 owing to increasing population of dogs and high prevalence of cancer in dogs as compared to cats

Lymphoma dominated the market among other cancer types in 2019, due to high mortality rate in companion animals

North America held the dominant share of the veterinary oncology market in 2019, due to favorable government policies, new product launches, and huge investment in oncology treatment

Asia Pacific is anticipated to witness lucrative growth due to increasing focus on animal health and expenditure, increasing number of pets being exposed to cancer, and government focus on animal safety and initiatives to curb cancer in pet animals

Some of the key companies are Boehringer Ingelheim; PetCure Oncology; Elanco; Accuray Incorporated; Varian Medical Systems; Zoetis; Karyopharm Therapeutics, Inc.; One Health; and Regeneus Ltd.

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Segment Scope
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates & Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary Research:
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
  • 1.7 List of Secondary Sources
  • 1.8 List of Primary Sources
  • 1.9 Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1:
    • 1.10.2 Objective 2:
    • 1.10.3 Market Definitions

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Competitive Outlook

Chapter 3 Veterinary Oncology Market Variables Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
    • 3.1.2 Ancillary market outlook
  • 3.2 Penetration & Growth Prospect Mapping by Technology, 2019
  • 3.3 User Perspective Analysis
    • 3.3.1 Market influencer analysis
  • 3.4 List of Key End Users
  • 3.5 Regulatory Framework
    • 3.5.1 Regulatory Landscape
  • 3.6 Technology Overview
    • 3.6.1 Veterinary Oncology timeline analysis
  • 3.7 Market Dynamics
    • 3.7.1 Market Driver Analysis
      • 3.7.1.1 Upsurge in the prevalence of cancer in pet animals
      • 3.7.1.2 Increasing research and investments in pet cancer
      • 3.7.1.3 Growing focus on animal safety
      • 3.7.1.4 Technological advancements in pet cancer treatment
    • 3.7.2 Market Restraints Analysis
      • 3.7.2.1 High cost of pet cancer treatment
      • 3.7.2.2 Lack of awareness among pet owners about pet disease
      • 3.7.2.3 Adverse effects of drugs used for pet cancer treatment
  • 3.8 Industry Analysis - Porter's
    • 3.8.1 Supplier Power
    • 3.8.2 Buyer Power
    • 3.8.3 Threat of Substitutes
    • 3.8.4 Threat of New Entrants
    • 3.8.5 Competitive Rivalry
  • 3.9 Veterinary Oncology - SWOT Analysis, by Factor (Political & Legal, Economic, Social and Technological)
    • 3.9.1 Political Landscape
    • 3.9.2 Economic Landscape
    • 3.9.3 Technology Landscape
    • 3.9.4 Social Landscape
  • 3.10 Major Deals and Strategic alliances

Chapter 4 Veterinary Oncology Market: Competitive Analysis

  • 4.1 Market Participation Categorization
  • 4.2 Competitive Analysis
    • 4.2.1 Company market position analysis
    • 4.2.2 Market leader
    • 4.2.3 Innovators
    • 4.2.4 Vendor Landscape
      • 4.2.4.1 List of veterinary Oncology service providers

Chapter 5 Veterinary Oncology Market: Therapy type analysis

  • 5.1 Therapy Type Business Analysis
    • 5.1.1 Surgery
      • 5.1.1.1 Surgery market estimates and forecasts, 2016 - 2027 (USD Million)
    • 5.1.2 Radiology
      • 5.1.2.1 Radiology market estimates and forecasts, 2016 - 2027 (USD Million)
    • 5.1.3 Chemotherapy
      • 5.1.3.1 Chemotherapy market estimates and forecasts, 2016 - 2027 (USD Million)
    • 5.1.4 Immunotherapy
      • 5.1.4.1 Immunotherapy market estimates and forecasts, 2016 - 2027 (USD Million)
    • 5.1.5 Others
      • 5.1.5.1 Others market estimates and forecasts, 2016 - 2027 (USD Million)

Chapter 6 Veterinary Oncology Market: Animal Type

  • 6.1 Animal Type Analysis
    • 6.1.1 Canine
      • 6.1.1.1 Canine market estimates and forecasts, 2016 - 2027 (USD Million)
    • 6.1.2 Feline
      • 6.1.2.1 Feline market estimates and forecasts, 2016 - 2027 (USD Million)

Chapter 7 Veterinary Oncology Market: Cancer Type

  • 7.1 Cancer Type Business Analysis
    • 7.1.1 Lymphoma
      • 7.1.1.1 Lymphoma market estimates and forecasts, 2016 - 2027 (USD Million)
    • 7.1.2 Mast Cell Cancer
      • 7.1.2.1 Mast Cell Cancer market estimates and forecasts, 2016 - 2027 (USD Million)
    • 7.1.3 Mammary and Squamous Cell Cancer
      • 7.1.3.1 Mammary and Squamous Cell Cancer market estimates and forecasts, 2016 - 2027 (USD Million)
    • 7.1.4 Others
      • 7.1.4.1 Others market estimates and forecasts, 2016 - 2027 (USD Million)

Chapter 8 Veterinary Oncology: Regional Market Analysis, By Therapy, Animal type, and Cancer Type 2016 - 2027 (USD Million)

  • 8.1 Regional Market Share Analysis, 2019 & 2027
  • 8.2 Regional Market Dashboard
  • 8.3 Regional Market Snapshot
  • 8.4 Market Size, & Forecasts and Trend Analysis, 2019 to 2027
    • 8.4.1 North America
      • 8.4.1.1 Veterinary oncology market estimates and segment forecasts, 2016 - 2027 (USD Million)
      • 8.4.1.2 U.S.
      • 8.4.1.2.1 Veterinary oncology market estimates and forecasts, 2016 - 2027 (USD Million)
      • 8.4.1.3 Canada
      • 8.4.1.3.1 Veterinary oncology market estimates and forecasts, 2016 - 2027 (USD Million)
    • 8.4.2 Europe
      • 8.4.2.1 Veterinary oncology market estimates and forecasts by countries, 2016 - 2027 (USD Million)
      • 8.4.2.2 U.K.
      • 8.4.2.2.1 Veterinary oncology market estimates and forecasts, 2016 - 2027 (USD Million)
      • 8.4.2.3 Germany
      • 8.4.2.3.1 Veterinary oncology market estimates and forecasts, 2016 - 2027 (USD Million)
    • 8.4.3 Asia Pacific
      • 8.4.3.1 Veterinary oncology market estimates and forecasts, 2016 - 2027 (USD Million)
    • 8.4.4 Latin America
      • 8.4.4.1 Veterinary oncology market estimates and forecasts, 2016 - 2027 (USD Million)
    • 8.4.5 MEA
      • 8.4.5.1 Veterinary oncology market estimates and forecasts by countries, 2016 - 2027 (USD Million)

Chapter 9 Company Profiles

  • 9.1 Boehringer Ingelheim International GmbH
    • 9.1.1 Company Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Benchmarking
    • 9.1.4 Strategic Initiatives
  • 9.2 Elanco
    • 9.2.1 Company Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Benchmarking
    • 9.2.4 Strategic Initiatives
  • 9.3 Zoetis
    • 9.3.1 Company Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Benchmarking
    • 9.3.4 Strategic Initiatives
  • 9.4 PetCure Oncology
    • 9.4.1 Company Overview
    • 9.4.2 Product Benchmarking
    • 9.4.3 Strategic Initiatives
  • 9.5 Accuray Incorporated
    • 9.5.1 Company Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Benchmarking
    • 9.5.4 Strategic Initiatives
  • 9.6 Varian Medical System, Inc.
    • 9.6.1 Company Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Benchmarking
    • 9.6.4 Strategic Initiatives
  • 9.7 Nippon Zenyaku Kogyo Co., Ltd.
    • 9.7.1 Company Overview
    • 9.7.2 Product Benchmarking
    • 9.7.3 Strategic Initiatives
  • 9.8 Morphogenesis, Inc.
    • 9.8.1 Company Overview
    • 9.8.2 Product Benchmarking
    • 9.8.3 Strategic Initiatives
  • 9.9 Karyopharm Therapeutics, Inc.,
    • 9.9.1 Company Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Benchmarking
    • 9.9.4 Strategic Initiatives
  • 9.10 Regeneus Ltd.
    • 9.10.1 Company Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Benchmarking
    • 9.10.4 Strategic Initiatives
  • 9.11 One Health
    • 9.11.1 Company Overview
    • 9.11.2 Product Benchmarking
    • 9.11.3 Strategic Initiatives

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 List of abbreviation
  • TABLE 3 List of veterinary oncology service providers
  • TABLE 4 North America veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 5 North America veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 6 North America veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)
  • TABLE 7 U.S. veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 8 U.S. veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 9 U.S. veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)
  • TABLE 10 Canada veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 11 Canada veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 12 Canada veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)
  • TABLE 13 Europe veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 14 Europe veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 15 Europe veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)
  • TABLE 16 U.K. veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 17 U.K. veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 18 U.K. veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)
  • TABLE 19 Germany veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 20 Germany veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 21 Germany veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)
  • TABLE 22 Asia Pacific veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 23 Asia Pacific veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 24 Asia Pacific veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)
  • TABLE 25 Latin America veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 26 Latin America veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 27 Latin America veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)
  • TABLE 28 MEA veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 29 MEA veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 30 MEA veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Veterinary Oncology executive summary, 2019, (USD Million)
  • Fig. 11 Veterinary Oncology market revenues, 2019, (USD Million)
  • Fig. 12 Segment outlook
  • Fig. 13 Strategy framework
  • Fig. 14 Parent market outlook
  • Fig. 15 Ancillary market outlook
  • Fig. 16 Penetration &growth prospect mapping by technology, 2019
  • Fig. 17 Veterinary oncology trend analysis
  • Fig. 18 Veterinary oncology timeline analysis
  • Fig. 19 Market trends & outlook
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Market restraints relevance analysis (Current & future impact)
  • Fig. 22 Porter's five force model
  • Fig. 23 Veterinary Oncology - SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 24 Market participant categorization
  • Fig. 25 Veterinary oncology company market position analysis
  • Fig. 26 Veterinary oncology market Therapy outlook: Key takeaways
  • Fig. 27 Veterinary oncology market: Therapy type movement analysis
  • Fig. 28 Global ENT market, 2016 - 2027 (USD Million)
  • Fig. 29 Global radiology market, 2016 - 2027 (USD Million)
  • Fig. 30 Global chemotherapy market, 2016 - 2027 (USD Million)
  • Fig. 31 Global immunotherapy market, 2016 - 2027 (USD Million)
  • Fig. 32 Global others market, 2016 - 2027 (USD Million)
  • Fig. 33 Veterinary oncology market animal type outlook: Key takeaways
  • Fig. 34 Veterinary oncology market: Technology type movement analysis
  • Fig. 35 Global canine market, 2016 - 2027 (USD Million)
  • Fig. 36 Global feline market, 2016 - 2027 (USD Million)
  • Fig. 37 Veterinary oncology market cancer type outlook: Key takeaways
  • Fig. 38 Veterinary oncology market: Cancer type movement analysis
  • Fig. 39 Global lymphoma market, 2016 - 2027 (USD Million)
  • Fig. 40 Global mast cell cancer market, 2016 - 2027 (USD Million)
  • Fig. 41 Global mammary and squamous cell cancer market, 2016 - 2027 (USD Million)
  • Fig. 42 Global others market, 2016 - 2027 (USD Million)
  • Fig. 43 Regional outlook, 2019 & 2027
  • Fig. 44 Regional market dashboard
  • Fig. 45 Regional marketplace: Key takeaways
  • Fig. 46 North America veterinary oncology, 2016 - 2027 (USD Million)
  • Fig. 47 North America veterinary oncology market by countries, 2016 - 2027 (USD Million)
  • Fig. 48 U.S. veterinary oncology market, 2016 - 2027 (USD Million)
  • Fig. 49 Canada veterinary oncology market, 2016 - 2027 (USD Million)
  • Fig. 50 Europe veterinary oncology, 2016 - 2027 (USD Million)
  • Fig. 51 Europe veterinary oncology market by countries, 2016 - 2027 (USD Million)
  • Fig. 52 U.K. veterinary oncology, 2016 - 2027 (USD Million)
  • Fig. 53 Germany veterinary oncology market, 2016 - 2027 (USD Million)
  • Fig. 54 Asia Pacific veterinary oncology market, 2016 - 2027 (USD Million)
  • Fig. 55 Latin America veterinary oncology market, 2016 - 2027 (USD Million)
  • Fig. 56 MEA veterinary oncology market, 2016 - 2027 (USD Million)